QUOTE AND NEWS
Forbes  Sep 15  Comment 
In recent trading, shares of ARIAD Pharmaceuticals Inc (NASD: ARIA) have crossed above the average analyst 12-month target price of $11.00, changing hands for $11.01/share. When a stock reaches the target an analyst has set, the analyst logically...
newratings.com  Aug 31  Comment 
BASEL (dpa-AFX) - ARIAD Pharmaceuticals Inc. (ARIA) has completed the rolling submission of its New Drug Application for Brigatinib to the FDA. The company is seeking accelerated approval of Brigatinib for patients with metastatic ALK-positive...
FierceBiotech  Aug 30  Comment 
Ariad finishes rolling NDA for lung cancer; wants sped-up review badams Tue, 08/30/2016 - 08:55
newratings.com  Aug 30  Comment 
WASHINGTON (dpa-AFX) - ARIAD Pharmaceuticals, Inc. (ARIA), a developer of precision therapies for patients with rare cancers, Tuesday said it has completed the rolling submission of the New Drug Application or NDA for its investigational...
Motley Fool  Aug 10  Comment 
Ariad's stock broke out in July. Here's why.
Forbes  Aug 8  Comment 
A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to...




 

Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.





References

Morningstar.com

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki